Class / Patent application number | Description | Number of patent applications / Date published |
424248100 | Mycobacterium (e.g., Mycobacterium tuberculosis, Calmette-Guerin bacillus (i.e., BCG), etc.) | 71 |
20080233153 | Vaccine compositions and adjuvant - The immune response of an animal to a target immunogen may be enhanced by use of a novel adjuvant which includes low concentrations of killed cells of | 09-25-2008 |
20080248066 | Modified free-living microbes, vaccine compositions and methods of use thereof - Free-living microbes are provided in which the nucleic acid has been modified so that the microbe is attenuated for proliferation and/or which comprise genetic mutations that attenuate the ability of the microbe to repair its nucleic acid. Methods of using the modified microbes for the loading, activation, and/or maturation of antigen-presenting cells are also provided. Vaccine compositions comprising the modified microbes and/or the antigen-presenting cells and methods of using the vaccines are also provided. The microbes may be further modified to include heterologous antigens, such as tumor antigens or infectious disease antigens, for use as a vaccine against cancer or infectious diseases. | 10-09-2008 |
20080260782 | Mycobacterium avium subspecies paratuberculosis vaccines and methods of using the same - The invention relates to vaccine compositions composed of at least one | 10-23-2008 |
20080311159 | Methods and Means for Diagnostics, Prevention and Treatment of Mycobacterium Infections and Tuberculosis Disease - The invention identifies a narrow subset of | 12-18-2008 |
20080317785 | Vaccine - The invention provides a vaccine comprising secreted protein derived from | 12-25-2008 |
20090004226 | Fusion proteins of mycobacterium tuberculosis - The present invention relates to compositions and fusion proteins containing at least two | 01-01-2009 |
20090060954 | Recombinant BCG Vaccine - A recombinant BCG vaccine being transformed with an expression vector that has a polynucleotide encoding a foreign antigenic protein, wherein the polynucleotide is a modified one in which the third position of each codon is substituted with G or C without a change of an amino acid. This recombinant BCG vaccine has an excellent expression rate of antigenic protein and, as a result, capable of inducing a sufficient immune response against target infectious disease, cancer, or the like at the same dose as that of the typical BCG vaccine. | 03-05-2009 |
20090220549 | REAGENTS FOR RECOMBINOGENIC ENGINEERING AND USE THEREOF - The present invention features homologous recombination methods and systems. The methods and systems promote highly efficient homologous recombination in cells (e.g., in prokaryotic cells). The methods and systems are useful, for example, in pharmaceutical drug development, vaccine development and cloning. | 09-03-2009 |
20090252765 | BACILLE CALMETTE-GUERIN (BCG)-BASED ANTI-ATHEROMA VACCINE AND METHODS OF USE THEREOF - The invention relates to a recombinant | 10-08-2009 |
20090263427 | Vaccines for mycoplasma bovis and methods of use - The invention of novel, effective vaccines against | 10-22-2009 |
20090280146 | CONTROL OF INTESTINAL INFLAMMATORY SYNDROMES WITH A PREPARATION OF KILLED OR NON INFECTIOUS BACTERIA - This invention relates to the use of a preparation of killed or non infectious Gram positive bacteria such as Gram positive facultative intracellular bacteria, for example mycobacteria, for the treatment of intestinal inflammatory syndromes such as Crohn's disease or ulcerative colitis. | 11-12-2009 |
20090304749 | Method of Producing Rough Strains of Bacteria and Uses Thereof - The present invention relates to a method of producing rough strains of a bacterium, such as | 12-10-2009 |
20090304750 | NOVEL PRIME-BOOST COMBINATIONS OF ATTENUATED MYCOBACTERIUM - The present invention provides vaccine compositions for effective induction of both mucosal and systemic immunity to pathogenic | 12-10-2009 |
20100008955 | METHOD AND KIT FOR DETECTING IF AN INDIVIDUAL IS SUSCEPTIBLE TO PROGRESS TO AN ACTIVE MYCOBACTERIAL DISEASE - A method for detecting whether an individual will progress to having active mycobacterial disease comprising determining whether the individual has a T cell response to one or more of the following mycobacterial antigens: CFP-10; Rv1989c; Rv3873; or Rv3878. | 01-14-2010 |
20100034855 | Compositions For Eliciting An Immune Response Against Mycobacterium Avium Subspecies Paratuberculosis - The invention provides compositions and method for stimulating an immunological response against | 02-11-2010 |
20100047286 | Recombinant BCG strains with enhanced ability to escape the endosome - strains that have an enhanced ability to elicit a Histocompatibility-Class I-restricted CD8 | 02-25-2010 |
20100062026 | POLY TLR ANTAGONIST - w or its components are found to have poly TLR antagonistic activity to induced TLRs by varieties of TLR ligands. The induced TLR against which inhibitory effect is seen includes TLR 3, 4, 5, 6, 7, 8, 9. They also display antagonistic activities to effects of TLR ligands. They are also useful in management of diseases wherein TLRs are over expressed, like sepsis, multiple sclerosis, optic neuritis, Chronic obstructive pulmonary diseases multiple myeloma etc. | 03-11-2010 |
20100092518 | Recombinant Intracellular Pathogen Immunogenic Compositions and Methods of Use - Immunogenic compositions comprising recombinant attenuated intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens are provided. Exemplary immunogenic compositions include, but are not limited to attenuated recombinant Mycobacteria expressing the major extracellular non-fusion proteins of Mycobacteria and/or other intracellular pathogens. Other embodiments are provided wherein the recombinant attenuated intracellular pathogen is auxotrophic. | 04-15-2010 |
20100112007 | TUBERCULOSIS VACCINE AND METHOD OF USING SAME - Provided is a pharmaceutical composition that includes one or more inactivated | 05-06-2010 |
20100112008 | TUBERCULOSIS NUCLEIC ACIDS, POLYPEPTIDES AND IMMUNOGENIC COMPOSITIONS - The present invention provides transcriptionally active Mtb polynucleotides, recombinant Mtb peptides and polypeptides, and immunogenic Mtb antigens. Immunogenic compositions are also provided that may be useful as recombinant, subunit and DNA vaccines. In addition the invention provides diagnostic kits for Mtb. | 05-06-2010 |
20100129407 | Tuberculosis Vaccine - The present invention relates to an isolated microorganism belonging to the genus | 05-27-2010 |
20100150966 | METHOD FOR THE DIAGNOSIS OF TUBERCULOSIS - Method for the diagnosis of a tuberculosis infection caused by Mycobacteria belonging to the Mycobacteria tuberculosis complex group (MTC) in an animal including a human being, which comprises in vitro-detection of cell-mediated immune response to OmpAtb and/or antibodies against OmpAtb in a sample taken from that animal. | 06-17-2010 |
20100166801 | SULFOGLYCOLIPID ANTIGENS, THEIR PROCESS OF PREPARATION, AND THEIR USE AGAINST TUBERCULOSIS - The present invention relates to compounds of the following general formula (I) their process of preparation and their use in the treatment or the prophylaxis of tuberculosis. | 07-01-2010 |
20100183676 | COMPOSITIONS COMPRISING OPA PROTEIN EPITOPES - The present invention relates to a composition comprising at least one purified Opa HV 1 protein epitope and at least one purified Opa HV2 protein epitope. The epitopes are preferably purified protein epitopes, preferably recombinant epitopes. The composition is preferably a pharmaceutical composition, more preferably a vaccine composition. The invention also relates to methods of immunisation and to specific formulations presented in the tables, and to novel nucleic acids encoding Opa alleles. | 07-22-2010 |
20100183677 | FUSION PROTEINS OF MYCOBACTERIUM TUBERCULOSIS - The present invention relates to compositions and fusion proteins containing at least two | 07-22-2010 |
20100233213 | Recombinant BCG Strains with Enhanced Ability to Escape the Endosome - strains that have an enhanced ability to elicit a MHC-Class I-restricted CD8 | 09-16-2010 |
20100297185 | MYCOBACTERIAL MUTANTS AFFECTING HOST APOPTOSIS - Provided are recombinant mycobacteria having a mutation in an nlaA gene or in a nuoG gene. Also provided are isolated and purified nlaA proteins and nuoG proteins from a | 11-25-2010 |
20100316674 | Immunogenic compositions against tuberculosis - Methods of preparing mutants of | 12-16-2010 |
20110020404 | DIAGNOSTIC METHOD AND KIT - The invention relates to methods for diagnosis of tuberculosis in an animal, the methods comprising determining the presence or absence of, or an immune response to a group of antigens comprising (i) the group consisting of Rv3616 antigen, MPB70 antigen, MPB83 antigen, and ESAT 6 antigen; or (ii) at least seven of the antigens of the group consisting of Rv3616 antigen, MPB70 antigen, MPB83 antigen, ESAT 6 antigen, CFP10 antigen, α crystalline 2 antigen, PE35 antigen, and PPE68 antigen. Also provided is a method for the diagnosis of the presence of tuberculosis in a reservoir animal e.g. a badger, said method comprising determining the presence or absence of, or an immune response to Rv3616 antigen, MPB70 antigen, and MPB83 antigen. Kits for carrying out the methods are also provided. | 01-27-2011 |
20110052637 | PROTEINS EXPRESSED BY MYCOBACTERIUM TUBERCULOSIS AND NOT BY BCG AND THEIR USE AS VACCINES - The present invention is directed to proteins expressed by | 03-03-2011 |
20110059136 | Methods and Compositions for Treating Inflammatory Bowel Disease - The present disclosure provides improved compositions comprising rifabutin, clarithromycin, and clofazimine for use in the treatment of Inflammatory Bowel Diseases. In one instance, the compositions may comprise a formulation of rifabutin, clarithromycin, and clofazimine in a single dosage form, such as a capsule, tablet, etc., with one or more specific excipients. | 03-10-2011 |
20110081382 | TREATMENT AND PREVENTION OF TUBERCULOSIS - The invention is within the field of immunology and microbiology, more specifically the field of mycobacteriology and is related to immunotherapy and prophylaxis of tuberculosis and related diseases. The composition useful for these purposes is disclosed, including the methods of using said composition. | 04-07-2011 |
20110086066 | Methods to Increase Transgene Expression From Bacterial-Based Delivery Systems by Co-Expressing Suppressors of the Eukaryotic Type I Interferon Response - Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells. Suppression of the eukaryotic Type I interferon response allows improved expression of the encoded transgene. | 04-14-2011 |
20110117133 | Novel Recombinant BCG Tuberculosis Vaccine Designed to Elicit Immune Responses to Mycobacterium Tuberculosis in all Physiological Stages of Infection and Disease - A vaccine against | 05-19-2011 |
20110129502 | Immunogenic Constructs - The present invention relates to molecules, which can be used to induce a therapeutic or prophylactic immune response against MAP. In particular, the present invention relates to polypeptides comprising an alipC polypeptide sequence, a gsd polypeptide sequence, a p12 polypeptide sequence and an mpa polypeptide sequence, wherein said ahpC polypeptide comprises the sequence of SEQ ID NO: 2, a variant thereof having more than 70% amino acid sequence identity to SEQ ID NO: 2 across the full length of SEQ ID NO: 2, or a fragment of at least 8 amino acids of SEQ ID NO: 2 which comprises an epitope; said gsd polypeptide comprises the sequence of SEQ ID NO: 6, a variant thereof having more than 70% amino acid sequence identity to SEQ ID NO: 6 across the full length of SEQ ID NO: 6, or a fragment of at least 8 amino acids of SEQ ID NO: 6 which comprises an epitope; said pi 2 polypeptide comprises the sequence of SEQ ID NO: 10, a variant thereof having more than 70% amino acid sequence identity to SEQ ID NO: 10 across the full length of SEQ ID NO: 10, or a fragment of at least 8 amino acids of SEQ ID NO: 10 which comprises an epitope; and said mpa polypeptide comprises the sequence of SEQ ID NO: 14, a variant thereof having more than 70% amino acid sequence identity to SEQ ID NO: 14 across the full length of SEQ ID NO: 14, or a fragment of at least 8 amino acids of SEQ ID NO: 14 which comprises an epitope. Preferably such a variant maintains the ability to generate an immune response against the unmodified polypeptide. | 06-02-2011 |
20110150932 | Constructing a DNA Chimera for Vaccine Development Against Leishmaniasis and Tuberculosis - A novel recombinant chimera of DNA construct having esat-6 region of | 06-23-2011 |
20110206732 | ALBUMIN FOR TREATING CANCER AND A PHARMACEUTICAL COMPOSITION COMPRISING THE COMBINATION OF AN ANTI-NEOPLASTIC AGENT AND ALBUMIN - The present invention relates to albumin as an active ingredient in a medicament for the treatment of cancer and to a pharmaceutical composition comprising at least one anti-neoplastic agent and albumin at a concentration of at least 2% w/v of the composition, in a pharmaceutically acceptable vehicle. The anti-neoplastic agent is preferably hydroxyurea, preferably at concentration between 10 μM and 1 mM, more preferably between 10 μM and 100 μM. The pharmaceutical composition of the invention is effective in the therapeutic treatment of cancer and advantageously shows reduced side effects in comparison with the administration of the anti-neoplastic agent alone. | 08-25-2011 |
20110223200 | NOVEL COMPOSITIONS AND METHODS - The present invention is directed to a polypeptide which comprises: (i) an Rv1753c protein sequence; (ii) a variant of an Rv1753c protein sequence; or (iii) an immunogenic fragment of an Rv1753c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis | 09-15-2011 |
20110243992 | METHODS OF ENHANCING THE IMMUNOGENICITY OF MYCOBACTERIA AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUBERCULOSIS, AND FIBROSING LUNG DISEASES - Whole-cell vaccines and methods for enhancing the immunogenicity of cellular microorganisms for use in producing protective immune responses in vertebrate hosts subsequently exposed to pathogenic bacteria or for use as vectors to express exogenous antigens and induce responses against other infectious agents or cancer cells. The present invention involves an additional method of enhancing antigen presentation by intracellular bacteria in a manner that improves vaccine efficacy. After identifying an enzyme that has an anti-apoptotic effect upon host cells infected by an intracellular microbe, the activity of the enzyme produced by the intracellular microbe is reduced by expressing a mutant copy of the enzyme, thereby modifying the microbe so that it increases immunogenicity. | 10-06-2011 |
20120003268 | SYNERGISTIC COMBINATION AND METHOD THEREOF - A method for the treatment of myeloma and thymoma by administering a therapeutically effective dose of | 01-05-2012 |
20120045476 | LIVE ATTENUATED MYCOPLASMA STRAINS - The present invention provides live, attenuated | 02-23-2012 |
20120082699 | Method of Producing Rough Strains of Bacteria and Uses Thereof - The present invention relates to a method of producing rough strains of a bacterium, such as | 04-05-2012 |
20120128720 | MYCOBACTERIUM MUTANTS FOR VACCINES WITH IMPROVED PROTECTIVE EFFICACY - Tuberculosis (TB) is a major health problem and currently, the only licensed TB vaccine is | 05-24-2012 |
20120141533 | MYCOBACTERIAL MUTANTS INDUCING IL-12 - Provided are mycobacteria deleted in at least a portion of a region 3 ESAT-6-like gene cluster. Also provided are mycobacteria comprising a mutation in an roc-1 gene. Additionally, vaccines comprising these mycobacteria are provided. Further provided are methods of making a recombinant mycobacterium, methods of inducing an immune response in a mammal, methods of inhibiting IL-12 production in a mammal, and methods of stimulating IL-12 production in a mammal. Vaccine adjuvants are also provided, as are methods of inducing immunity to a target antigen in a mammal. | 06-07-2012 |
20120189662 | Identification of virulence associated regions RD1 and RD5 leading to improve vaccine of M. bovis BCG and M. microti - The present invention relates to a strain of | 07-26-2012 |
20120276144 | Pro-Apoptotic Bacterial Vaccines To Enhance Cellular Immune Responses - Whole-cell vaccines and methods for their use in producing protective immune responses in vertebrate hosts subsequently exposed to pathogenic bacteria. The present invention involves a method of enhancing antigen presentation by intracellular bacteria in a manner that improves vaccine efficacy. After identifying an enzyme that has an anti-apoptotic effect upon host cells infected by an intracellular microbe, the activity of the enzyme is reduced, thereby modifying the microbe so that it increases immunogenicity. Also, the present invention provides a method of incrementally modifying enzyme activity to produce incrementally attenuated mutants of the microbe from which an effective vaccine candidate can be selected. | 11-01-2012 |
20130022638 | Tuberculosis Vaccine - The present invention relates to an isolated microorganism belonging to the genus | 01-24-2013 |
20130052229 | COMPOUNDS AND METHODS FOR DIAGNOSIS AND IMMUNOTHERAPY OF TUBERCULOSIS - Compounds and methods for diagnosing tuberculosis or for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more | 02-28-2013 |
20130101623 | ATTENUATED MYCOBACTERIAL STRAIN AS NOVEL VACCINE AGAINST TUBERCULOSIS - The present invention provides a novel attenuated vaccine for tuberculosis. Furthermore, when used as a subcutaneous vaccine, the present invention induces a higher level of protection than the current vaccine. Finally, the present invention results in less tissue damage and a lower number of colony forming units (CFU) in the lungs compared to subjects vaccinated with BCG. | 04-25-2013 |
20130142828 | BACTERIAL RIBONUCLEIC ACID CELL WALL COMPOSITIONS AND METHODS OF MAKING AND USING THEM - The present invention relates to novel mycobacterial compositions containing RNA and cell walls, and methods for making and using these compositions. These compositions have immune stimulating and anti-cancer activity. The present invention also relates to a synthetic medium for the cultivation of mycobacteria. | 06-06-2013 |
20130171193 | THERAPEUTIC VACCINATION AGAINST ACTIVE TUBERCULOSIS - The invention provides a method for therapeutic treatment of a patient having active tuberculosis (TB), the method comprising: administering to the patient a recombinant adenovirus vector that comprises nucleic acid encoding the Ag85A, Ag85B and TB10.4 antigens of | 07-04-2013 |
20130202642 | IMMUNOGENIC COMPOSITIONS AGAINST TUBERCULOSIS - Methods of preparing mutants of | 08-08-2013 |
20130273110 | Tuberculosis Vaccine And Method Of Using Same - Provided is a pharmaceutical composition that includes one or more inactivated | 10-17-2013 |
20130330375 | Therapeutic Cancer Vaccine - The present invention relates to vaccine(s) comprising cancer cells expressing antigen(s), excipients, optionally adjuvant wherein the said antigen(s) is expressed on contacting the said cancer cell with p38 inducer, for use in treatment of Cancer. The vaccine composition induces specific immune response against homologous and heterologus cancer cells of the tissue/organ. The invention also provides method of preparing the same. | 12-12-2013 |
20130337011 | RECOMBINANT MYCOBCTERIUM AS A VACCINE - The invention relates to a recombinant | 12-19-2013 |
20140004151 | Antigens and Epitopes Derived From Mycobacterium Tuberculosis | 01-02-2014 |
20140147468 | LPRG AS A CHAPERONE OF IMMUNE ADJUVANTS - An adjuvant combination that stimulates immune activation or response includes a hydrophobic immune adjuvant and a pathogen derived lipoprotein that chaperones the hydrophobic immune adjuvant to an immune receptor. | 05-29-2014 |
20140170189 | Bacterial Ribonucleic Acid Cell Wall Compositions and Methods of Making and Using Them - The present invention relates to novel bacterial and mycobacterial compositions containing RNA and cell walls, and methods for making and using these compositions. These compositions have immune stimulating and anti-cancer activity. | 06-19-2014 |
20140178434 | METHOD AND COMPOSITIONS - A method of preparing a compound of formula (III): | 06-26-2014 |
20140186400 | METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASES - The invention features methods for increasing or maintaining the number of functional cells of a predetermined type, for example, insulin producing cells of the pancreas, blood cells, spleen cells, brain cells, heart cells, vascular tissue cells, cells of the bile duct, or skin cells, in a mammal (e.g., a human patient) that has injured or damaged cells of the predetermined type. | 07-03-2014 |
20140271719 | Global Gene Regulators (GGR) As Vaccine Candidates Against Paratuberculosis - Described herein is a | 09-18-2014 |
20140302095 | MYCOBACTERIUM TUBERCULOSIS PORINS AND TOXINS AND RELATED METHODS - Provided herein are isolated polypeptides comprising the amino-terminal domain of | 10-09-2014 |
20140356397 | Immunogenic Treatment Of Cancer - The present invention provides an immunomodulator for use in the treatment and/or control of a neoplastic disease in a patient intended to undergo immunogenic cell death therapy simultaneously, separately or sequentially with administration of the immunomodulator. The therapy can be selected from microwave irradiation, targeted radiotherapy, embolization, cryotherapy, ultrasound, high intensity focused ultrasound, cyberknife, hyperthermia, radiofrequency ablation, cryoablation, electrotome heating, hot water injection, alcohol injection, embolization, radiation exposure, photodynamic therapy, laser beam irradiation, and combinations thereof. | 12-04-2014 |
20150093414 | MODIFIED ANTIGENS - Modified Rv3616c proteins and their use as medicaments, particularly for the prevention of reactivation of tuberculosis. | 04-02-2015 |
20150140039 | IMMUNOLOGICAL MARKERS FOR ADJUVANT THERAPY IN MELANOMA - The present invention concerns embodiments for determining whether an individual in need of immunotherapy will be responsive to the immunotherapy. Determination of one or more SNPs in particular genes is predictive of responsiveness to immunotherapy, particularly in individuals that have melanoma, for example. In certain embodiments, the SNPs are in ITGB2, SP1 1O, ILIB, IL23R, SLC11A1, IL12B, CCR5, TNF, ILIO, CXCL12, BTNL2, ANKRD20A4, CD 14, P2X7, IL8, TLR2, and/or CD209. | 05-21-2015 |
20150309030 | PODXL IN BLADDER CANCER - There is provided a method for determining whether a mammalian subject having a bladder cancer belongs to a first or a second group, wherein the prognosis of subjects of the second group is worse than the prognosis of subjects of the first group, comprising the steps of: a) evaluating an amount of PODXL in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; b) comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, c1) concluding that the subject belongs to the second group; and if said sample value is lower than or equal to said reference value, c2) concluding that the subject belongs to the first group. | 10-29-2015 |
20150374816 | DESIGN OF SHORT OLIGONUCLEOTIDES AS VACCINE ADJUVANTS AND THERAPEUTIC AGENTS - The invention provides a method of treating a microbial infection in a subject and a method of improving an immune system response in a subject against a disease, condition, infection, or virus thereof, by administering an effective amount of a nucleoside, short oligonucleotide compound or an analog thereof, or a pharmaceutically acceptable salt, racemate, enantiomer, diastereomer, geometric isomer, or tautomer thereof. In addition, the invention provides methods for treating or preventing a viral infection, bacterial infection, parasitic infection, or fungal infection in a subject (such as, a human). The compounds of the invention include, for example, di-, and trinucleotide compounds as provided herein. The compounds of the invention are useful for different therapeutic applications including, such as, prophylactics and therapeutics. The invention also provides design and synthesis of a compound that is useful for various therapeutic applications as mentioned herein. | 12-31-2015 |
20160074494 | CANCER THERAPY - The present invention resides in the preparation of a medicament to aid in the treatment of cancer. According to the invention there is a whole cell | 03-17-2016 |
20160106832 | TREATMENT OF CANCER WITH NALTREXONE - The present invention provides novel therapeutic applications of low dose naltrexone (LDN). Said applications have been determined in light of the discovery by the present inventors that naltrexone acts as an antagonist of Toll-like receptor 9 (TLR9), an innate immune receptor which elicits the production of inflammatory cytokines when agonized. Chronic inflammation and TLR9 overexpression are characteristics of a number of disorders, including certain cancers. Accordingly, the present invention provides novel uses of naltrexone in the treatment of a subject having a disorder characterised by TLR9 overexpression and/or overactivity of TLR9-mediated signalling. The present invention also provides novel uses of naltrexone in the supportive care of subject having a tumour/cancer, and methods of treating and providing supportive care to a subject, comprising the administration of naltrexone. | 04-21-2016 |
20160151475 | Bacterial Ribonucleic Acid Cell Wall Compositions and Methods of Making and Using Them | 06-02-2016 |
20160175420 | IMMUNOGENIC COMPOSITIONS AGAINST TUBERCULOSIS | 06-23-2016 |